期刊文献+

乳腺癌细胞膜蛋白的SELDI-TOF-MS分析 被引量:1

Screening differential membrane proteins of cultured breast cancer cell lines
下载PDF
导出
摘要 目的比较乳腺癌细胞株和正常乳腺上皮细胞膜蛋白指纹图谱,为乳腺癌亚细胞蛋白组学的研究奠定基础。方法试剂盒提取两株乳腺癌细胞株MDA-MB-231,MCF-7及一株乳腺正常上皮细胞HBL-100的膜蛋白,SEL-DI-TOF-MS分析蛋白指纹图谱,寻找差异蛋白。结果在分子量2kD-100kD范围内3株细胞均可检测到近100个蛋白点,MDA-MB-231和MCF-7与HBL-100相比,膜蛋白差异点分别为32个和34个(P<0.05),其中7.8kD,8.3kD和8.8kD的蛋白在两株癌细胞中表达均降低,9.6kD的蛋白在两株癌细胞中表达均增高。结论 SELDI-TOF-MS可以快速灵敏地检测到乳腺癌亚细胞蛋白水平的差异,为乳腺癌早期诊断提供依据。 Objective To screen differential membrane proteins by comparing protein fingerprinting between breast cancer and normal breast epithelial cell lines cultured in vitro,which may lay a foundation for sub-cellular protein biomarker of breast cancer.Methods Membrane proteins of two breast cancer cell lines MDA-MB-231,MCF-7 and one normal breast epithelium cell line HBL-100 were extracted,and the protein fingerprinting were measured by surface enhanced laser desorption/ionization time-of-flight mass spectrometry(SELDI-TOF-MS) for 50 times.Differential proteins were analyzed and screened by Bio-maker Wizard Software.Results About 100 protein peaks were observed on protein fingerprinting spectra ranged from 2 kD to 100 kD,among which 32 and 34 membrane protein peaks of them showed significant difference between MDA-MB-231 and MCF-7 when compared with HBL-100(P〈0.05).Protein peaks at 7.8 kD,8.3 kD and 8.8 kD were down-regulated in both breast cancer cell lines,while protein peaks at 9.6 kD were up-regulated.Conclusion SELDI-TOF-MS can detect membrane proteins of breast cancer cell lines accurately and sensitively,which applies a new method for subcellular protein biomarkers of breast cancer.
出处 《中国实验诊断学》 2012年第3期381-384,共4页 Chinese Journal of Laboratory Diagnosis
基金 国家高技术研究发展计划(863计划)课题(编号2006AA02090408) 四川省卫生厅科研课题(编号070058)
关键词 膜蛋白 SELDI-TOF-MS 乳腺癌 蛋白组学 早期诊断 breast cancer membrane proteins SELDI-TOF-MS early diagnosis
  • 相关文献

参考文献9

  • 1Jemal A,Tiwari RC,Murray T,et al.Cancer statistics[J].CACancer J Clin.2004,54(1):8.
  • 2Chagpar AB,McMasters KM.Trends in mammography and clini-cal breast examination:apopulation-based study[J].J Surg Res,2007,140(2):214.
  • 3Hinestrosa MC,Dickersin K,Klein P,et al.Shaping the future ofbiomarker research in breast cancer to ensure clinical relevance[J].Nat Rev Cancer,2007,7(4):309.
  • 4Kanzaki A,Yoi M,Nakayama K,et al.Expression of multidrugresistanc-related transporters in human breast carcinoma[J].JCancer Res,2001,92(4):452.
  • 5Roberts SS,Mendona-Torres MC,Jensen K.et al.GABA recep-tor expression in benign and malignant thyroid tumors[J].PatholOncol Res.,2009,15(4):645.
  • 6Garcia Pedrero JM,Fernandez MP,Morgan RO,et al.AnnexinA1down-regulation in head and neck cancer is associated withepithelial differentiation status[J].Am J Pathol,2004,164(1):73.
  • 7Adam P J,Boyd R,Tyson KL,et al.Comprehensive proteomic a-nalysis of breast cancer cell membranes reveals unique proteinswith potential roles in clinical Cancer[J].J Biol Chem,2003,278(8):6482.
  • 8Mannel F,Medda V,Tonti GA,et al.Protein profile analysis ofthe breast microenvironment to differentiate healthy women frombreast cancer patients[J].Expert Rev Proteomics,2009,6(1):43.
  • 9Leong S,Christopherson RI,Baxter RC,et al.Profiling of apop-totic changes in human breast cancer cells using SELDI-TOFmass spectrometry[J].Cell Physiol Biochem,2007,20(5):579.

同被引文献22

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部